A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The characterization sections of biologics license applications (BLAs) approved by the United States Food and Drug Administration (FDA) between 2000 and 2015 were investigated to examine the extent of the use of mass spectrometry. Mass spectrometry was found to be integral to the characterization of these biotherapeutics. Of the 80 electronically submitted monoclonal antibody and protein biotherapeutic BLAs included in this study, 79 were found to use mass spectrometric workflows for protein or impurity characterization. To further examine how MS is being used in successful BLAs, the applications were filtered based on the type and number of quality attributes characterized, the mass spectrometric workflows used (peptide mapping, intact mass analysis, and cleaved glycan analysis), the methods used to introduce the proteins into the gas phase (ESI, MALDI, or LC-ESI), and the specific types of instrumentation used. Analyses were conducted over a time course based on the FDA BLA approval to determine if any trends in utilization could be observed over time. Additionally, the different classes of protein-based biotherapeutics among the approved BLAs were clustered to determine if any trends could be attributed to the specific type of biotherapeutic. Graphical Abstract ᅟ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Top Down proteomics: Facts and perspectives
Catherman, A. D., Skinner, O. S., & Kelleher, N. L. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.041 · Cited by 507
Cited by
Wasalathanthri, D. P., Rehmann, M. S., Song, Y., Gu, Y., Mi, L., Shao, C., Chemmalil, L., Lee, J., Ghose, S., Borys, M. C., et al. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27461 · Cited by 177
Modern Sensor Tools and Techniques for Monitoring, Controlling, and Improving Cell Culture Processes
Reyes, S. J., Durocher, Y., Pham, P. L., & Henry, O. (2022) · Processes · doi:10.3390/pr10020189 · Cited by 130
Multi‐Attribute Method for Quality Control of Therapeutic Proteins
Rogstad, S., Yan, H., Wang, X., Powers, D., Brorson, K., Damdinsuren, B., & Lee, S. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03808 · Cited by 123
Self-citationJin, Y., Lin, Z., Xu, Q., Fu, C., Zhang, Z., Zhang, Q., Pritts, W. A., & Ge, Y. (2019) · mAbs · doi:10.1080/19420862.2018.1525253 · Cited by 68
Sawyer, W. S., Srikumar, N., Carver, J., Chu, P. Y., Shen, A., Xu, A., Williams, A. J., Spiess, C., Wu, C., Liu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917383117 · Cited by 55
“Comparing these pools against the highperforming pools (3, 4, 7, 8) showed a decrease in overall intensity of correctly paired bispecific antibodies as well as an increase in the overall intensity of half-antibodies, which both contribute to the lower percent of correct pair matching.”
Background
Metadata
- Authors
- Rogstad, S., Faustino, A., Ruth, A., Keire, D., Boyne, M., & Park, J.
- Venue
- Journal of the American Society for Mass Spectrometry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-11-21
- Volume
- 28
- Issue
- 5
- Pages
- 786-794
- ISSN
- 1044-0305 (ISSN-L)
- OpenAlex
- W2555577306
- Cited by
- 115
- References
- 1
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications. https://app.cochat.ai/papers/10.1007/s13361-016-1531-9
- The paper
- Rogstad, S., Faustino, A., Ruth, A., Keire, D., Boyne, M., & Park, J. (2017). A Retrospective Evaluation of the Use of Mass Spectrometry in FDA Biologics License Applications. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1007/s13361-016-1531-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.